XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, William W.L. Choi, Jooryung Huh, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Benjamin M. ParsonsJ. Han van Krieken, Miguel A. Piris, Jane N. Winter, Fredrick Hagemeister, Lapo Alinari, Yong Li, Michael Andreeff, Bing Xu*, Ken H. Young

*Corresponding author

Research output: Contribution to journalLetterpeer-review

6 Citations (Scopus)
4 Downloads (Pure)
Original languageEnglish
Article number148
JournalJournal of Hematology & Oncology
Volume13
Issue number1
DOIs
Publication statusPublished - 1 Dec 2020

Keywords

  • BCL2
  • DLBCL
  • HGBCL
  • MYC
  • Selinexor
  • TP53 mutation
  • XPO1

Fingerprint

Dive into the research topics of 'XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53'. Together they form a unique fingerprint.

Cite this